Both PARP1 and PARP2 expression displayed significant correlations with MSI status, the molecular subtypes of CRC, aneuploidy and BRAF mutations but not TP53 mutations, FGA or LST. This evidence concerns the gene PARP2 and colorectal carcinoma.